The Therapeutically Applicable Research to Generate Effective Treatments (TARGET) program is a community resource project, and data are made available rapidly after validation for use by other researchers.
TARGET Program Attribution in Publications and Presentations
TARGET requests that authors who use data from TARGET acknowledge the appropriate Project Team(s) in their work by referencing the TARGET dataset in accordance with the Data Use Certification posted at dbGaP [1]. If investigators desire to collaborate with TARGET members, they should contact the PI of the disease project team.
We suggest the following language: "The results published here are in whole or part based upon data generated by the Therapeutically Applicable Research to Generate Effective Treatments (https://ocg.cancer.gov/programs/target [2]) initiative, phs000218. The data used for this analysis are available at https://portal.gdc.cancer.gov/projects [3]."
| Disease | dbGaP Sub-study ID |
|---|---|
| Acute Lymphoblastic Leukemia (ALL) Pilot Phase 1 | phs000463 |
| Acute Lymphoblastic Leukemia (ALL) Expansion Phase 2 | phs000464 |
| Acute Myeloid Leukemia (AML) | phs000465 |
|
Cancer Model Systems (MDLS): Cell Lines and Xenografts
(including Pediatric Preclinical Testing Program––PPTP)
|
phs000469 |
| Clear Cell Sarcoma of the Kidney (CCSK) | phs000466 |
| Neuroblastoma (NB) | phs000467 |
| Osteosarcoma (OS) | phs000468 |
| Rhabdoid Tumor (RT) | phs000470 |
| Wilms Tumor (WT) | phs000471 |
For questions, please contact the TARGET Publications Committee at ocg@mail.nih.gov [4].
Researchers who plan to prepare manuscripts containing descriptions of TARGET pediatric cancer data that would be of comparable scope to an initial TARGET disease-specific comprehensive, global analysis publication, and journal editors who receive such manuscripts, are strongly encouraged to coordinate their independent reports with TARGET’s publication schedule. Specifically, comparable scope is defined as global genome-wide analysis of TARGET disease-specific data from one or more than one platform or a trans-TARGET manuscript. If you have questions, do not hesitate to contact ocg@mail.nih.gov [4].